The risk of prostate cancer increases faster with age than any other form of cancer. The increasing life span of our aging population places a greater number of men at risk for this disease. One such man was my father. With little or no warning, Robert Benjamin Ablin went into acute urinary retention and was diagnosed with metastatic cancer of the prostate. This was in 1978, in an era of limited ability to diagnose prostate cancer. He was diagnosed in a late stage of his disease; he died one year later, in August 1979.

 

 

BRIEF BIOGRAPHICAL DETAILS OF RICHARD J. ABLIN, Ph.D. 

Prior to joining the Arizona Cancer Center and the University of Arizona College of Medicine as Research Professor of Immunobiology and Pathology, Dr. Ablin served consecutively as Director, Scientific Investigation at Tetragenex Pharmaceuticals, Inc. (Park Ridge, NJ), and Director, Immunobiology Unit, Department of Urology and Research Associate Professor of Urology, State University of New York at Stony Brook School of Medicine. He is President of the Robert Benjamin Ablin Foundation for Cancer Research, founded in memory of his father, since 1979. 

Dr. Ablin received his Ph.D. in Microbiology from the State University of New York at Buffalo in 1967, following which he continued his training in immunology as a United States Public Health Service Postdoctoral Fellow at the Medical School under the late renowned Distinguished Professor Ernest Witebsky.  Dr. Ablin recently received the degree of D.Sc., honoris causa, from Lake Forest College, his undergraduate alma mater, and was honored as the recipient of the First Award for Scientific Excellence by The Haakon Ragde Foundation for Advanced Cancer Studies in recognition “for his invaluable contribution to humankind and exceptional scientific insight and valiant fight against cancer.”

Dr. Ablin discovered prostate-specific antigen (PSA) in 1970, for which he was a nominee for the Lasker Award in 1997. His discovery of PSA led to the development of the PSA test. A pioneer of cryosurgery and the concept of “cryoimmunotherapy” for the treatment of cancer, Dr. Ablin has extensive experience in cancer research, particularly in the study of the development and metastasis of cancer.  A member of Phi Beta Kappa and various professional societies, including the American Association for Cancer Research, the American Association of Immunologists, the British Association of Surgical Oncology, the New York Academy of Sciences, and Sigma Xi, he was a founding member and Vice President (1977-80) of the American College of Cryosurgery and served as President (1977-80) of the International Society of Cryosurgery, who named him Honorary Life-Time President in 1980.  Dr. Ablin is a Diplomat of the American Board of Clinical Immunology and Allergy and certified by the American Academy of Microbiology in Public Health and Medical Laboratory Microbiology. Cited in several biographical references, including American Men and Women of Science, Who’s Who of Emerging Leaders in America and Who’s Who in the World, he has been an invited speaker at numerous national and international scientific meetings and has contributed numerous articles to professional journals and texts. Dr. Ablin is co-editor of the book series Cancer Metastasis -Biology and Treatment and serves on the editorial board of several journals, including Clinical and Vaccine Immunology, Current Opinion in Oncology, International Journal of Oncology and Journal of Translational Medicine.